Publication Topic

Bean K, Jones SA, Chakrapani A, Vijay S, Wu T, Church H, … Jensen I, et al. 2024. Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK. Int J Neonatal Screen 10(3):45; doi: 10.3390/ijns10030045.

Chew DS, Sacks NC, Emden MR, Cyr PL, Sherwood R, Pokorney SD. 2024. Catheter ablation for supraventricular tachycardia and health resource utilization and expenditures: A propensity-matched cohort study. Int J Cardiol 403(May 15):131831; doi: 10.1016/j.ijcard.2024.131831. PMID: 38331201.

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr PL, Sawyer EK, Stephen CD, et al. 2024. Burden of illness and mortality in men with adrenomyeloneuropathy: A retrospective cohort study. Orph J Rare Dis 19(1):270; doi: 10.1186/s13023-024-0326-w. PMID: 39020416.

Hernandez L, Davies S, Li C, Reddick E, Jensen I. A cost-consequence analysis of ponatinib versus imatinib in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia in the United States. Abstract EE165, ISPOR 2024 (Top 5% Finalist).

Minshall ME, Liu Y, Wagner A, Jensen IS, Corman S. The cost for of chronic lung allograft dysfunction (CLAD) in lung transplant (LTX) recipients by stage 1-4: A claims database analysis. Abstract EE70, ISPOR 2024.

Suh M, Movva N, Jiang X, Reichert H, Pastula ST, Sacks NC, Frankenfeld C, Fryzek JP, Simões AF. 2024. Healthcare utilization among infants covered by Medicaid and newly diagnosed with respiratory syncytial virus. Open Forum Infect Dis 11(4)::ofae174; doi: 10.1093/ofid/ofae174. PMID: 38595954.

Davies S, Boller E, Chase J, Beaubrun A, Miller C, Jensen I. 2024. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses. J Med Econ 27(1):430–441; doi: 10.1080/13696998.2024.2313391.

Davison NJ, Guthrie NL, Medland S, Lupinacci P, Nordyke RJ, Berman MA. 2024. Cost-effectiveness analysis of a prescription digital therapeutic in Type 2 diabetes. Adv Ther 41(2):806-825; doi: 10.1007/s12325-023-02752-2. PMID: 38170435.

Wagner TD, Westrich KD, Nordyke RJ, Campbell JD. 2024. Inflation-adjusted analysis of ICER’s Unsupported Price Increase reports: Contextualizing drug spending changes. J Med Econ 27(1):1537-1541; doi: 10.1080/13696998.2024.2428109. PMID: 39626873.

Garrison K, Zhang W, Jensen I, Shah A, Brown S, Stephenson B, Yim C. Cost-utility analysis of roflumilast cream for plaque psoriasis, including intertriginous, from the Canadian societal perspective. Abstract EE303, ISPOR EU 2023.